The presence of CD8+ T cells inside the tumor or at the tumor periphery, known as tumor-infiltrating lymphocytes (TILs), and increased PD-1 expression within T cells have also been associated with a more robust clinical response and outcome [18,19]. The gene discussed is CD8A; the disease is neoplasm.